Friday, May 24, 2013 Last update: 4:06 AM
Company Tech News as it Breaks
Genzyme
News articles for Genzyme:
Wednesday, April 24, 2013
- Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC StudyGenzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today positive top-line results from the TOPIC trial for AUBAGIO (teriflunomide). The ... read more
Thursday, April 18, 2013
- Genzyme Convenes 13th European Fabry Disease RoundtableGenzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that the 13th European Fabry Disease Roundtable will take place April ... read more
Monday, April 8, 2013
- Genzyme’s Once-daily, Oral AUBAGIO® (teriflunomide) Approved in Argentina for the Treatment of Relapsing Multiple SclerosisGenzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) has ... read more
Friday, March 22, 2013
- Genzyme Receives Positive CHMP Opinion in the European Union for Once-daily, Oral AUBAGIO® to Treat Relapsing-Remitting Multiple SclerosisGenzyme, a Sanofi Company (EURONEXT: SAN and NYSE: SNY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the ... read more
Thursday, March 21, 2013
- Effect of Genzyme’s LEMTRADA™ Maintained in Patients Beyond Two-Year Pivotal MS StudiesGenzyme, a Sanofi Company (EURONEXT: SAN and NYSE: SNY), announced today interim results from the first year of the extension study of LEMTRADA™ ... read more
Tuesday, March 12, 2013
- Genzyme’s Multiple Sclerosis Franchise Featured at AANGenzyme, a Sanofi Company (EURONEXT: SAN and NYSE: SNY), announced today that data from its AUBAGIO® (teriflunomide) and LEMTRADATM (alemtuzumab) multiple sclerosis ... read more
Monday, March 4, 2013
- Genzyme’s Head of Rare Diseases Honored by the Genetic Disease FoundationGenzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that Genzyme’s Head of Rare Diseases, Rogerio Vivaldi, MD, has been honored ... read more
Wednesday, February 27, 2013
- Genzyme Recognizes International Rare Disease Day with Global Awareness Programs and Launch of Third Annual Patient Advocacy Leadership (PAL) AwardsGenzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced its support of International Rare Disease Day with a series of initiatives ... read moreGenzyme Receives Company Award from European Organisation for Rare Diseases (EURORDIS)Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that it has received a Company Award from EURORDIS, the largest European patient ... read more
Friday, February 15, 2013
- Genzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for Gaucher DiseaseGenzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced positive new data from the Phase 3 ENGAGE and ENCORE studies of eliglustat ... read more
Tuesday, January 29, 2013
- Genzyme and Isis Announce FDA Approval of KYNAMRO™ (mipomersen sodium) Injection for the Treatment of Homozygous Familial HypercholesterolemiaGenzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that the U.S. Food and Drug Administration (FDA) has approved its ... read more
Sunday, January 27, 2013
- Genzyme’s LEMTRADA™ (alemtuzumab) Application for MS Accepted for Review by the FDAGenzyme, a Sanofi Company (EURONEXT: SAN and NYSE: SNY), announced that the U.S. Food and Drug Administration (FDA) has accepted for review the ... read more
Friday, December 7, 2012
- Genzyme Receives European Label Expansion for ThyrogenGenzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced it has received European Commission approval of a product label expansion for ... read more
Monday, November 26, 2012
- Genzyme Honors Innovation in Gaucher Disease Research through Its 2012 Gaucher Generation Program AwardsGenzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced the recipients of the 2012 Gaucher Generation Program awards, an annual ... read more